Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 09/28/16 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
09/07/16Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
09/06/16Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
09/01/16Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
08/18/16Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
Upcoming EventsMore >>
Eiger BioPharmaceuticals at Eiger BioPharmaceuticals at Piper 28th Annual Healthcare Conference
Eiger BioPharmaceuticals at AASLD Boston
Eiger BioPharmaceuticals at Oppenheimer Life Sciences Summit
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.